Alkermes PLC (NASDAQ:ALKS) dropped 9.3% during trading on Friday after UBS AG lowered their price target on the stock from $57.00 to $54.00. UBS AG currently has a neutral rating on the stock. Alkermes PLC traded as low as $49.52 and last traded at $49.85. Approximately 2,192,899 shares traded hands during mid-day trading, an increase of 207% from the average daily volume of 715,140 shares. The stock had previously closed at $54.97.

ALKS has been the subject of a number of other reports. Mizuho set a $81.00 target price on shares of Alkermes PLC and gave the company a “buy” rating in a research report on Saturday, October 21st. ValuEngine cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Jefferies Group LLC set a $69.00 target price on shares of Alkermes PLC and gave the company a “buy” rating in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $63.55.

In related news, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the sale, the chief accounting officer now directly owns 70,455 shares in the company, valued at $3,613,636.95. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total transaction of $82,365.00. Following the transaction, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $521,645. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,066 shares of company stock valued at $930,280. 5.34% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Toronto Dominion Bank boosted its stake in Alkermes PLC by 12.7% during the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after buying an additional 212 shares during the period. Daiwa SB Investments Ltd. purchased a new position in Alkermes PLC during the second quarter worth about $166,000. Greenwood Capital Associates LLC boosted its stake in Alkermes PLC by 1.1% during the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after buying an additional 41 shares during the period. US Bancorp DE boosted its stake in Alkermes PLC by 366.4% during the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after buying an additional 3,122 shares during the period. Finally, Insight Capital Research & Management Inc. purchased a new position in Alkermes PLC during the second quarter worth about $232,000. 98.39% of the stock is owned by institutional investors.

The company’s market capitalization is $7.66 billion. The firm has a 50-day moving average of $51.15 and a 200 day moving average of $55.08.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.24%. The company had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same quarter in the prior year, the company posted ($0.09) EPS. The company’s quarterly revenue was up 20.6% compared to the same quarter last year. On average, equities research analysts forecast that Alkermes PLC will post ($0.04) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/alkermes-plc-alks-shares-down-9-3-following-analyst-downgrade/1660760.html.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.